Determined the high dose of OCU410ST to be the maximum tolerated dose No serious adverse events have been reported Approved proceeding to Phase 2 using high and medium doses of OCU410ST MALVERN, Pa., ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, ...

The DSMB was established in 2023 to oversee the first-in-human aspects of the trial, ensuring ongoing patient safety, data integrity, and scientific validity in line with Clearmind's commitment to ...

Please provide your email address to receive an email when new articles are posted on . The ArMaDa trial is investigating unilateral subretinal administration of OCU410, a gene therapy for geographic ...

NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on ...

The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease PITTSBURGH, March 4, 2025 /PRNewswire/ -- ...

BERWYN, PA.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Annovis Bio announced it received a ...

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug ...

Data Monitoring Committees (DMCs) play a pivotal role in safeguarding participant safety and ensuring the integrity of clinical trials. Operating independently from trial sponsors and investigators, ...

Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...